The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease models
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increasing evidence suggests that α-synuclein also forms soluble oligomers, and that oligomers are more toxic than fibrils.
“Increasing evidence suggests that α-synuclein also forms soluble oligomers, and that oligomers are more toxic than fibrils [33,34,35].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“In agreement with the impor- tance of soluble oligomers for neurodegeneration, other studies have suggested that aggregation intermediates are the pathologically relevant species in Alzheimer and Huntington disease (Saudou et al, 1998; Lesne et al, 2006).”
ResultRetractedCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316
Structural Rearrangements of Membrane Proteins Probed by Water-Edited Solid-State NMR Spectroscopy
Ader, C., Schneider, R., Seidel, K., Etzkorn, M., Becker, S., & Baldus, M. (2009) · Journal of the American Chemical Society · doi:10.1021/ja806306e · Cited by 124
Self-citation
Flagged first, then by citations
Research works printed but not linked: 48
- Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M (2005) Release of long‐range tertiary interactions potentiates aggregation of natively unstructured alpha‐synuclein. Proc Natl Acad Sci USA 102: 1430–1435 · DOI
- Bischof J, Maeda RK, Hediger M, Karch F, Basler K (2007) An optimized transgenesis system for Drosophila using germ‐line‐specific phiC31 integrases. Proc Natl Acad Sci USA 104: 3312–3317 · DOI
- Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94 · DOI
- Chen L, Feany MB (2005) Alpha‐synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657–663 · DOI
- Cheon M, Chang I, Mohanty S, Luheshi LM, Dobson CM, Vendruscolo M, Favrin G (2007) Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput Biol 3: 1727–1738 · DOI
- Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y (2007) Evidence of fibril‐like beta‐sheet structures in a neurotoxic amyloid intermediate of Alzheimer′s beta‐amyloid. Nat Struct Mol Biol 14: 1157–1164 · DOI
- Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury Jr PT (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha‐synuclein mutations linked to early‐onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97: 571–576 · DOI
- Cookson MR, van der Brug M (2008) Cell systems and the toxic mechanism(s) of alpha‐synuclein. Exp Neurol 209: 5–11 · DOI
- Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S (2006) Alpha‐synuclein blocks ER‐Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324–328 · DOI
- Eliezer D, Kutluay E, Bussell Jr R, Browne G (2001) Conformational properties of alpha‐synuclein in its free and lipid‐associated states. J Mol Biol 307: 1061–1073 · DOI
- Feany MB, Bender WW (2000) A Drosophila model of Parkinson′s disease. Nature 404: 394–398 · DOI
- Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury Jr PT (2007) The impact of the E46K mutation on the properties of alpha‐synuclein in its monomeric and oligomeric states. Biochemistry 46: 7107–7118 · DOI
- Fung BM, Khitrin AK, Ermolaev K (2000) An improved broadband decoupling sequence for liquid crystals and solids. J Magn Reson 142: 97–101 · DOI
- Ganetzky B, Flanagan JR (1978) On the relationship between senescence and age‐related changes in two wild‐type strains of Drosophila melanogaster. Exp Gerontol 13: 189–196 · DOI
- George JM, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15: 361–372 · DOI
- Goedert M (2001) Alpha‐synuclein and neurodegenerative diseases. Nat Rev Neurosci 2: 492–501 · DOI
- Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N (2008) The phosphorylation state of Ser‐129 in human alpha‐synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 105: 763–768 · DOI
- Greenbaum EA, Graves CL, Mishizen‐Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI (2005) The E46K mutation in alpha‐synuclein increases amyloid fibril formation. J Biol Chem 280: 7800–7807 · DOI
- Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA (2008) Hypothesis‐based RNAi screening identifies neuroprotective genes in a Parkinson′s disease model. Proc Natl Acad Sci USA 105: 728–733 · DOI · Paper page
- Heise H, Celej MS, Becker S, Riedel D, Pelah A, Kumar A, Jovin TM, Baldus M (2008) Solid‐state NMR reveals structural differences between fibrils of wild‐type and disease‐related A53T mutant alpha‐synuclein. J Mol Biol 380: 444–450 · DOI
- Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M (2005) Molecular‐level secondary structure, polymorphism, and dynamics of full‐length alpha‐synuclein fibrils studied by solid‐state NMR. Proc Natl Acad Sci USA 102: 15871–15876 · DOI
- Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V (2002) Dependence of alpha‐synuclein aggregate morphology on solution conditions. J Mol Biol 322: 383–393 · DOI
- Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of alpha‐synuclein to brain vesicles is abolished by familial Parkinson′s disease mutation. J Biol Chem 273: 26292–26294 · DOI
- Kugler S, Hahnewald R, Garrido M, Reiss J (2007) Long‐term rescue of a lethal inherited disease by adeno‐associated virus‐mediated gene transfer in a mouse model of molybdenum‐cofactor deficiency. Am J Hum Genet 80: 291–297 · DOI
- Kuwahara T, Koyama A, Gengyo‐Ando K, Masuda M, Kowa H, Tsunoda M, Mitani S, Iwatsubo T (2006) Familial Parkinson mutant alpha‐synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J Biol Chem 281: 334–340 · DOI
- Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, Blakely RD, Wong G (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha‐synuclein. J Neurochem 86: 165–172 · DOI
- Lashuel HA, Lansbury Jr PT (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore‐forming toxins? Q Rev Biophys 39: 167–201 · DOI
- Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha‐synuclein mice: implications for neurodegenerative disorders. Science 287: 1265–1269 · DOI
- Masuda M, Dohmae N, Nonaka T, Oikawa T, Hisanaga S, Goedert M, Hasegawa M (2006) Cysteine misincorporation in bacterially expressed human alpha‐synuclein. FEBS Lett 580: 1775–1779 · DOI
- Meredith GE, Sonsalla PK, Chesselet MF (2008) Animal models of Parkinson′s disease progression. Acta Neuropathol 115: 385–398 · DOI
- Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M (1999) Both familial Parkinson′s disease mutations accelerate alpha‐synuclein aggregation. J Biol Chem 274: 9843–9846 · DOI
- Nass R, Blakely RD (2003) The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annu Rev Pharmacol Toxicol 43: 521–544 · DOI
- Norris EH, Giasson BI, Lee VM (2004) Alpha‐synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 60: 17–54 · DOI
- Opazo F, Krenz A, Heermann S, Schulz JB, Falkenburger BH (2008) Accumulation and clearance of alpha‐synuclein aggregates demonstrated by time‐lapse imaging. J Neurochem 106: 529–540 · DOI
- Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B (1999) alpha‐Synuclein shares physical and functional homology with 14‐3‐3 proteins. J Neurosci 19: 5782–5791 · DOI
- Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha‐synuclein biology and pathobiology. Science 302: 1772–1775 · DOI
- Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha‐synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27: 3338–3346 · DOI
- Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self‐propagating, molecular‐level polymorphism in Alzheimer′s beta‐amyloid fibrils. Science 307: 262–265 · DOI · Paper page
- Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55–66 · DOI
- Seidel K, Lange A, Becker S, Hughes CE, Heise H, Baldus M (2004) Protein solid‐state NMR resonance assignments from (C‐13, C‐13) correlation spectroscopy. Phys Chem Chem Phys 6: 5090–5093 · DOI
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha‐synuclein in Lewy bodies. Nature 388: 839–840 · DOI · Paper page
- Sunde M, Blake C (1997) The structure of amyloid fibrils by electron microscopy and X‐ray diffraction. Adv Protein Chem 50: 123–159 · DOI
- Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant alpha‐synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9: 2683–2689 · DOI
- van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA (2008) C. elegans model identifies genetic modifiers of alpha‐synuclein inclusion formation during aging. PLoS Genet 4: e1000027 · DOI
- Vilar M, Chou HT, Luhrs T, Maji SK, Riek‐Loher D, Verel R, Manning G, Stahlberg H, Riek R (2008) The fold of alpha‐synuclein fibrils. Proc Natl Acad Sci USA 105: 8637–8642 · DOI · Paper page
- Volles MJ, Lansbury Jr PT (2007) Relationships between the sequence of alpha‐synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 366: 1510–1522 · DOI
- Zhou DH, Kloepper KD, Winter KA, Rienstra CM (2006) Band‐selective 13C homonuclear 3D spectroscopy for solid proteins at high field with rotor‐synchronized soft pulses. J Biomol NMR 34: 245–257 · DOI
- Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR (2000) Overexpression of human alpha‐synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon‐derived cells. Brain Res 866: 33–43 · DOI
Cited by
Sorted by citations
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases
Guo, J. L., & Lee, V. M. Y. (2014) · Nature Medicine · doi:10.1038/nm.3457 · Cited by 641
A soluble α-synuclein construct forms a dynamic tetramer
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T. T., Liao, J., Auclair, J. R., Johnson, D., Landeru, A., Simorellis, A. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113260108 · Cited by 478
α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton
Ordonez, D. G., Lee, M. K., & Feany, M. B. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.036 · Cited by 227
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132
Lizama, B. N., Kahle, J., Catalano, S. M., Caggiano, A. O., Grundman, M., & Hamby, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076251 · Cited by 54
Metadata
- Authors
- Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., Kumar, A., Riedel, D., Fichtner, L., Voigt, A., Braus, G. H., Giller, K., Becker, S., Herzig, A., Baldus, M., Jäckle, H., Eimer, S., Schulz, J. B., Griesinger, C., & Zweckstetter, M.
- Venue
- The EMBO Journal
- Published
- 2009-09-10
- Volume
- 28
- Issue
- 20
- Pages
- 3256-3268
- ISSN
- 0261-4189
- 1460-2075
- Cited by
- 432
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
